Loomis, Sayles & Company
RCKT icon

Loomis, Sayles & Company’s Rocket Pharmaceuticals RCKT Stock Holding History

Loomis, Sayles & Company’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-899,510
Closed -$39.8M – 925
2021
Q2 		$39.8M Sell
899,510
-18,214
-2% -$791K 0.05% 209
2021
Q1 		$40.7M Sell
917,724
-2,922
-0.3% -$160K 0.05% 185
2020
Q4 		$50.5M Sell
920,646
-156,130
-14% -$5.69M 0.07% 130
2020
Q3 		$24.6M Buy
1,076,776
+111,192
+12% +$2.74M 0.04% 195
2020
Q2 		$20.2M Buy
+965,584
New +$17.4M 0.03% 219

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Loomis, Sayles & Company's RCKT Position: Q3 2021 in Review

Loomis, Sayles & Company sold out of Rocket Pharmaceuticals (RCKT) in Q3 2021, closing a stake of 899,510 shares — an estimated $39.8M sold.

Loomis, Sayles & Company first reported a position in RCKT in Q2 2020 and held it in 5 quarters. The position peaked at $50.5M in Q4 2020. 146 funds tracked by Wall St. Rank hold RCKT as of Q3 2021.

  • Loomis, Sayles & Company reported no remaining Rocket Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 899,510 Rocket Pharmaceuticals shares in Q3 2021, an estimated $39.8M.
  • Loomis, Sayles & Company first reported a position in Rocket Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Loomis, Sayles & Company's Rocket Pharmaceuticals position peaked at $50.5M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2021.

Based on Loomis, Sayles & Company's 13F filing for Q3 2021, filed 12 Nov 2021.